POXEL Stock Overview
A clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.23 |
| 52 Week High | €0.95 |
| 52 Week Low | €0.22 |
| Beta | 1.67 |
| 11 Month Change | -26.53% |
| 3 Month Change | -62.92% |
| 1 Year Change | -34.73% |
| 33 Year Change | -95.57% |
| 5 Year Change | -96.94% |
| Change since IPO | -96.75% |
Recent News & Updates
Recent updates
Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%
Mar 27
Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?
May 07How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 16How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?
Nov 17
Shareholder Returns
| POXEL | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -10.0% | -5.6% | -0.06% |
| 1Y | -34.7% | -26.5% | -2.5% |
Return vs Industry: POXEL underperformed the French Biotechs industry which returned -28.2% over the past year.
Return vs Market: POXEL underperformed the French Market which returned -2.1% over the past year.
Price Volatility
| POXEL volatility | |
|---|---|
| POXEL Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: POXEL's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: POXEL's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 6 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
| POXEL fundamental statistics | |
|---|---|
| Market cap | €12.47m |
| Earnings (TTM) | -€35.09m |
| Revenue (TTM) | €1.98m |
6.3x
P/S Ratio-0.4x
P/E RatioIs POXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POXEL income statement (TTM) | |
|---|---|
| Revenue | €1.98m |
| Cost of Revenue | €1.98m |
| Gross Profit | €1.00k |
| Other Expenses | €35.09m |
| Earnings | -€35.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Dec 09, 2024
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 0.051% |
| Net Profit Margin | -1,771.33% |
| Debt/Equity Ratio | -99.1% |
How did POXEL perform over the long term?
See historical performance and comparison